Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc. (Aegerion), which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
View Top Employees from Novelion Therapeutics| Website | http://www.novelion.com |
| Ticker | NVLN |
| Revenue | $138.4 million |
| Employees | 3 (3 on RocketReach) |
| Founded | 1981 |
| Phone | (604) 707-7001 |
| Technologies | |
| Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Drug Discovery, Health Care, Science and Engineering, Therapeutics |
| Web Rank | 7 Million |
| Keywords | Sol Barer, Novelion Investor Relations, Dr Mark Corrigan Synereca, Qlt Inc. Sedar, Aegerion Pharmaceuticals Inc. |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 325412 Companies |
Looking for a particular Novelion Therapeutics employee's phone or email?
Novelion Therapeutics Questions
The Novelion Therapeutics annual revenue was $138.4 million in 2024.
Roger Louis is the Acting Head Research and Development of Novelion Therapeutics.
3 people are employed at Novelion Therapeutics.
The NAICS codes for Novelion Therapeutics are [3254, 32, 32541, 325, 325412].
The SIC codes for Novelion Therapeutics are [28, 283].
Top Novelion Therapeutics Employees
-
5+3
-
ViewAlexandra Berlet
Regional Rare Disease Manager, West at Novelion Therapeutics
Bothell, Washington, United States1
Related Companies
